





***FIG. 1***

**FIG. 2**

**FIG. 3**

**FIG. 4**





FIG. 5

Population	Treatment		LsMean Diff. (SE)	60% CI	p-value
			JNJ - Placebo	JNJ - Placebo	
Enriched	JNJ-67953964 10mg		-2.14 (1.252)	[-3.20, -1.09]	0.0443
Full	JNJ-67953964 10mg		-3.09 (1.049)	[-3.97, -2.21]	0.0017

← Favours Active -- Favours Placebo →

-4 -3 -2 -1 0 1 2 3 4

FIG. 6

**FIG. 7**

Population	Treatment		LsMean Diff. (SE) JNJ - Placebo	80% CI JNJ - Placebo	p-value
Enriched	JNJ-67953964 10mg		-0.70 (0.865)	[-1.81, 0.41]	0.4188
Full	JNJ-67953964 10mg		-0.85 (0.735)	[-1.79, 0.10]	0.2503

← Favours Active Favours Placebo →

-4 -3 -2 -1 0 1 2 3 4

FIG. 8




FIG. 9




FIG. 10A












FIG. 10B

**FIG. 11****FIG. 12**

**FIG. 13****FIG. 14**

**FIG. 15****FIG. 16**

**FIG. 17****FIG. 18**




FIG. 19






FIG. 20A

**FIG. 20B****FIG. 21**




FIG. 22





FIG. 23

**FIG. 24**

SUBSTITUTE SHEET (RULE 26)




FIG. 25






FIG. 26



Treatment A: 2X 5 mg oral capsule administered in the morning, after at least 10-hour overnight fasting.
Treatment B: 1X 10 mg Formulation Concept 1 administered in the morning, after at least 10-hour overnight fasting.


FIG. 27



Treatment A: 2X 5 mg oral capsule administered in the morning, after at least 10-hour overnight fasting.
Treatment B: 1X 10 mg Formulation Concept 1 administered in the morning, after at least 10-hour overnight fasting.

PK profiles are not different for aticaprant between capsule and unmilled API tablet

FIG. 28



Treatment B: 1X 10 mg Formulation Concept 1 administered in the morning, after at least 10-hour overnight fasting.
Treatment C: 1X 5 mg Formulation Concept 1 administered in the morning, after at least 10-hour overnight fasting.

FIG. 29




FIG. 30






FIG. 31




Treatment B: 1X 10 mg Formulation Concept 1 administered in the morning, after at least 10-hour overnight fasting.
Treatment D: 1X 10 mg Formulation Concept 1 administered in the morning, approximately 30 minutes after the start of a standardized high-fat breakfast following at least 10-hour overnight fasting.


FIG. 32



Treatment B: 1X 10 mg Formulation Concept 1 administered in the morning, after at least 10-hour overnight fasting.
Treatment D: 1X 10 mg Formulation Concept 1 administered in the morning, approximately 30 minutes after the start of a standardized high-fat breakfast following at least 10-hour overnight fasting.

FIG. 33

**FIG. 34**

**FIG. 35**





FIG. 36

**FIG. 37**